Work

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.483

Authors: Dickon Hayne, Nicole Swarbrick, Stephen McCombie, Andrew Moe, Cynthia Hawks, Pravin Viswambaram, Ciara Conduit, Elizabeth Chien Hern Liow, Lisa Spalding, Jarrad Bothe, Tom Ferguson, Andrew James Martin, Ian D. Davis, Andrew David Redfern

Institutions: The University of Western Australia, Fiona Stanley Hospital, Peter MacCallum Cancer Centre, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, The University of Sydney, National Health and Medical Research Council, Eastern Health, Monash University

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4212978414

Cites:

Cited by: 3

Related to: 10